Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
Company Directory
Abbott Vascular
3200 Lakeside Drive
Santa Clara
CA 95054-2807
USA
[t] 001 847 937 3802
Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses.

Abbott Vascular is focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education.

Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognised internationally for their safety and effectiveness in treating patients with vascular disease.

Abbott receives CE Mark for world's longest coronary drug eluting stent
22 May, 2013
Abbott receives the CE Mark in Europe for the XIENCE Xpedition 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to the heart due to coronary artery disease (CAD).
Minimally invasive system for mitral regurgitation demonstrates positive clinical results
11 March, 2013
Abbott reports data from the EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) High Surgical Risk cohort evaluating the company's first-in-class catheter-based MitraClip System for the treatment of mitral regurgitation (MR).
Drug eluting bioresorbable vascular scaffold is to be evaluated in US patients with coronary artery disease
09 January, 2013
The ABSORB III clinical trial is initiated in patients in the USA.
New drug eluting stent system offers delivery benefits
04 January, 2013
Abbott's XIENCE Xpedition Everolimus Eluting Coronary Stent System receives US Food and Drug Administration (FDA) approval and is launching immediately in the USA, providing physicians with a next-generation technology that claims to offer the largest size matrix in the US market.
XIENCE Xpedition Everolimus eluting stent receives CE Mark
21 August, 2012
Abbott's XIENCE Xpedition Everolimus Eluting Coronary Stent System receives CE Mark in Europe for the treatment of coronary artery disease.
Abbott receives approval for XIENCE PRIME stent in Japan
10 April, 2012
Abbott receives approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
Clinical trial starts to evaluate bioresorbable vascular scaffold
09 December, 2011
Abbott is reporting the initiation of the ABSORB II, which is the first randomized, controlled, multi-centre clinical trial to evaluate the safety, efficacy and performance of the Absorb bioresorbable vascular scaffold (BVS) compared to the company's XIENCE PRIME Everolimus Eluting Coronary Stent System.
Bioresorbable vascular scaffold reinforces clinical performance
15 November, 2011
Abbott is reporting positive long-term data from the two-stage ABSORB trial, which is evaluating the ABSORB drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease.
XIENCE PRIME stent receives FDA approval
03 November, 2011
Abbott receives US Food and Drug Administration (FDA) approval for the next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
Abbott starts enrolling US patients in EXCEL stent trial
05 October, 2011
Abbott is beginning to enroll US patients in the EXCEL (Evaluation of XIENCE PRIME or XIENCE V versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial.
Abbott starts bioresorbable vascular scaffold trial
09 September, 2011
Abbott is initiating ABSORB BTK, an international clinical trial evaluating the safety and efficacy of the ABSORB bioresorbable vascular scaffold (BVS) for the treatment of below-the-knee (BTK) critical limb ischemia. Critical limb ischemia, a severe form of peripheral artery disease (PAD), occurs when blocked vessels impair blood flow to the lower extremities, which can eventually lead to limb amputation.
First Japanese patient is treated with Abbott's Bioresorbable Vascular Scaffold
17 August, 2011
The first patient in Japan is treated with Abbott's ABSORB bioresorbable vascular scaffold (BVS) as part of the ABSORB EXTEND clinical trial.
Second phase of drug eluting BSV ABSORB trial reports positive one-year results
05 April, 2011
Abbott is releasing positive one-year results from 101 patients enrolled in the second phase of the ABSORB trial evaluating the world's first drug eluting Bioresorbable Vascular Scaffold (BVS) for the treatment of coronary artery disease.
Coronary dilatation catheters receive regulatory clearance in Japan and US
02 February, 2011
Abbott receives regulatory clearance in the USA and approval in Japan for its TREK and MINI-TREK Coronary Dilatation Catheters for the treatment of coronary artery disease.
Abbott's XIENCE PRIME Everolimus eluting coronary stent receives CE Mark
24 January, 2011
Abbott receives CE Mark for its XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of critical limb ischemia (CLI) or severe claudication (pain) of the lower leg.
First drug eluting bioresorbable vascular scaffold receives CE Mark approval
11 January, 2011
Abbott receives CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease.
Abbott reports positive nine-month results ABSORB BVS trial
27 September, 2010
Abbott is reporting positive nine-month results from the first 45 patients enrolled in the second stage of the ABSORB trial.
Bioresorbable vascular scaffold demonstrates positive 30-day results
17 March, 2010
Patients treated with Abbott's bioresorbable vascular scaffold (BVS), under clinical investigation in Europe, demonstrates no cases of blood clots (thrombosis), no need for repeat procedures (ischemia-driven target lesion revascularization) and a low rate of major adverse cardiac events (MACE(1) rate of 2.0 percent) at 30 days.
Abbott unveils three-year data on fully bioabsorbable stent technology
18 November, 2009
Abbott reveals three-year data from the first 30 patients in the first phase of the ABSORB clinical trial, demonstrating that its fully bioabsorbable drug eluting coronary stent successfully treated coronary artery disease and was absorbed into the walls of treated arteries.
Vulnerable Plaque insight gained from Prospect study
25 September, 2009
Prospect study by Abbott Vascular enhances knowledge about the role of vulnerable plaque in the progression of coronary heart disease
Low stent thrombosis rate with Xience V
25 September, 2009
Compare trial results demonstrate high safety levels of Abbot’s Xience V drug eluting coronary stent system
Impressive results for Xience drug eluting stent
22 September, 2009
Sustained clinical advantages demonstrated during US trials of the Xience V Everolimus Eluting Coronary Stent system from Abbott Vascular
Abbott’s event line-up for TCT 2009
17 September, 2009
A distinguished set of speakers on coronary care have been lined up by Abbott Vascular for the Transcatheter Cardiovascular Therepeutics conference
Drug eluting stent approval in China
15 September, 2009
Approval received by Abbott Vascular for its Xience V Drug eluting stent from the Chinese food and drug administration giving the company access to a very large healthcare market
Evalve acquisition announced by Abbott
11 September, 2009
Developer of minimally invasive cardiac valve repair technology has been bought out by Abbott
Coronary Stent system launched internationally
02 September, 2009
Abbott Vascular has gone international with its Xience Prime Drug Eluting Coronary Stent for treating coronary disease
Abbott receives Health Canada approval for the Xience V stent to treat CAD
24 August, 2009
Abbott receives approval from Health Canada for the Xience V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD).
Xience V USA post-approval study is expanded
14 August, 2009
Abbott expands the company's Xience V USA post-approval study designed to evaluate the safety and effectiveness of the company's market-leading XIENCE V Everolimus Eluting Coronary Stent System in a real-world clinical setting out to five years.
Abbott's Xience Prime stent system receives CE Mark recognition
23 June, 2009
Abbott has received the CE Mark for its next-generation Xience Prime Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
Sixth-generation Embolic Protection System offers solution for carotid artery stenting procedures
12 June, 2009
Abbott launches the sixth-generation Emboshield NAV6 Embolic Protection System for use in carotid artery stenting procedures.
Abbott initiates US clinical trial of the Absolute Pro Peripheral Self-Expanding Stent
02 April, 2009
Abbott initiates MOBILITY, a clinical trial in the USA that is studying the safety and efficacy of the Absolute Pro Peripheral Self-Expanding Stent System in patients with iliac artery disease.
Abbott's SPIRIT II clinical trial demonstrates long term data
30 March, 2009
Long-term data from Abbott's SPIRIT II clinical trial demonstrates that the clinical advantages of the Xience V Everolimus Eluting Coronary Stent System continued to increase between two and three years compared to the Taxus Express2 Paclitaxel-Eluting Coronary Stent System / Taxus Liberte Paclitaxel-Eluting Coronary Stent System (Taxus).
Abbott begins second phase of ABSORB clinical trial
24 March, 2009
Abbott is initiating the next phase of the ABSORB clinical trial to evaluate the safety and performance of the company's fully bioabsorbable drug eluting coronary stent.
ABSORB clinical trial of bioabsorbable drug eluting stent reports two year analysis
13 March, 2009
Analysis from the ABSORB clinical trial demonstrated that Abbott's bioabsorbable drug eluting stent, currently in development, successfully treated coronary artery disease and was absorbed into the walls of treated arteries within two years.
Abbott launches next-generation high-pressure balloon dilatation catheter
10 March, 2009
Abbott has launched its Voyager NC Coronary Dilatation Catheter, which is a next-generation balloon dilatation catheter with high-pressure capability designed to optimise the treatment of patients with coronary artery disease (CAD) during angioplasty procedures.
Trial results show performance benefits of Xience V stent
27 January, 2009
Data from the Spirit III US pivotal trial evaluating the Xience V Everolimus Eluting Coronary Stent System has been published online in Circulation and demonstrates that Abbott's market-leading Xience V outperforms the Taxus Express2 Paclitaxel-Eluting Coronary Stent System (Taxus) in reducing major adverse cardiac events (MACE) at two years.
Abbott begins SPIRIT Small Vessel clinical trial to evaluate 2.25mm Xience V stent
18 December, 2008
Abbott has started the SPIRIT Small Vessel clinical trial designed to evaluate a 2.25mm size of the Xience V Everolimus Eluting Coronary Stent System.
Xience V Everolimus Eluting Coronary Stent wins 2008 Chicago Innovation Award
29 October, 2008
Abbott’s Xience V Everolimus Eluting Coronary Stent System has received a 2008 Chicago Innovation Award.
Abbott starts Xience V USA post-approval study at six hospital centres
10 July, 2008
Abbott has started the Xience V USA post-approval study, with six hospital centres already recruiting and enrolling patients just one week after the US Food and Drug Administration approved the Xience V Everolimus Eluting Coronary Stent System.
Xience V Everolimus Eluting Coronary Stent System receives USA FDA approval
03 July, 2008
The US Food and Drug Administration (FDA) has approved the Xience V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
Abbott seeks to market Xience V stent in Japan
02 June, 2008
Abbott has submitted an application for a Marketing Authorization License to Japan's Ministry of Health, Labour and Welfare (MHLW)/ Pharmaceuticals and Medical Devices Agency (PMDA) to gain approval for its Xience V Everolimus Eluting Coronary Stent System to treat coronary artery disease.
Abbott launches new fast, safe vessel closure device
16 May, 2008
Abbott has unveiled its StarClose SE Vascular Closure System, a next-generation vessel closure device that provides fast, safe and secure closure of the femoral artery access site following a catheterization procedure.
New study demonstrates new DES outcome results
23 April, 2008
A new study has demonstrated that use of Abbott's Xience V Everolimus Eluting Coronary Stent System in patients with coronary artery disease resulted in a significant 50 percent reduction in vessel renarrowing (in-segment late loss) at eight months.
World’s first trial of fully bioabsorbable drug eluting coronary stent shows no thrombosis
14 March, 2008
Results from Absorb, the world's first clinical trial of a fully bioabsorbable drug eluting stent for the treatment of coronary artery disease, have demonstrated no stent thrombosis, no clinically driven target lesion revascularizations (retreatment of a diseased lesion), and a low (3.3 percent) rate of major adverse cardiac events (MACE) in 30 patients out to one year.
Abbott’s new 2.25mm diameter stent prepares for launch in Europe, Asia and Latin America
11 March, 2008
Abbott has received CE Mark approval for a 2.25mm version of its Xience V Everolimus Eluting Coronary Stent System, offering physicians a smaller stent based upon the proven efficacy, positive safety results and deliverability of Xience V.
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo